| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/JNCI/89.17.1285 |
| P698 | PubMed publication ID | 9293919 |
| P2093 | author name string | Y Wang | |
| R D Burk | |||
| R H Angeletti | |||
| S L Romney | |||
| A S Kadish | |||
| G Y Ho | |||
| R Ledwidge | |||
| P433 | issue | 17 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1285-1293 | |
| P577 | publication date | 1997-09-01 | |
| P1433 | published in | Journal of the National Cancer Institute | Q400279 |
| P1476 | title | Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia | |
| P478 | volume | 89 |
| Q34121681 | A conserved E7-derived cytotoxic T lymphocyte epitope expressed on human papillomavirus 16-transformed HLA-A2+ epithelial cancers |
| Q48035556 | A phase II trial of interleukin-12 in patients with advanced cervical cancer: clinical and immunologic correlates. Eastern Cooperative Oncology Group study E1E96. |
| Q36923830 | Association of serum cytokines with oral HPV clearance |
| Q39877403 | CD3zeta expression and T cell proliferation are inhibited by TGF-beta1 and IL-10 in cervical cancer patients. |
| Q45375334 | CD4+ T cells against human papillomavirus-18 E7 in patients with high-grade cervical lesions associate with the absence of the virus in the cervix |
| Q43824472 | Cancer of the uterine cervix may be significantly associated with a gene polymorphism coding for increased IL-10 production |
| Q33998922 | Cell-mediated immune response to human papillomavirus infection |
| Q84520481 | Conjugation of HPV16 E7 to cholera toxin enhances the HPV-specific T-cell recall responses to pulsed dendritic cells in vitro in women with cervical dysplasia |
| Q34953499 | Development of therapeutic HPV vaccines |
| Q60321494 | Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine |
| Q48956742 | Epitope specificity and longevity of a vaccine-induced human T cell response against HPV18. |
| Q24802483 | Ethnic differences in allelic distribution of IFN-g in South African women but no link with cervical cancer |
| Q53356618 | Genetic polymorphisms of FAS and FASL (CD95/CD95L) genes in cervical carcinogenesis: An analysis of haplotype and gene-gene interaction. |
| Q36976268 | HPV Vaccines: today and in the Future |
| Q37581762 | HPV as a model for the development of prophylactic and therapeutic cancer vaccines. |
| Q34448633 | HPV clearance in postpartum period of HIV-positive and negative women: a prospective follow-up study. |
| Q42468679 | HPV-18 confers resistance to TNF-alpha in organotypic cultures of human keratinocytes. |
| Q40814266 | HPV16 L1E7 chimeric virus-like particles induce specific HLA-restricted T cells in humans after in vitro vaccination |
| Q36052694 | Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III |
| Q84753092 | Human papillomavirus 16-specific T cell responses in classic HPV-related vulvar intra-epithelial neoplasia. Determination of strongly immunogenic regions from E6 and E7 proteins |
| Q35069346 | Human papillomavirus therapy for the prevention and treatment of cervical cancer |
| Q60655522 | Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L |
| Q47977608 | Human papillomavirus type 16-specific T cell responses and their association with recurrence of cervical disease following treatment |
| Q33808144 | Human papillomavirus type 33 E7 peptides presented by HLA-DR*0402 to tumor-infiltrating T cells in cervical cancer |
| Q37345134 | Human papillomavirus vaccine and cervical cancer prevention |
| Q36223920 | Human papillomavirus-related cervical and anal disease in HIV-infected individuals in the era of highly active antiretroviral therapy |
| Q36550902 | Human papillomaviruses and cervical cancer |
| Q81299133 | Immune responses to human papillomavirus in genital tract of women with cervical cancer |
| Q34305225 | Immunity to oncogenic human papillomaviruses |
| Q40863595 | Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7. |
| Q44280889 | Increase of human papillomavirus-16 E7-specific T helper type 1 response in peripheral blood of cervical cancer patients after radiotherapy |
| Q60647118 | Increased carcinoembryonic antigen expression in cervical intraepithelial neoplasia grade 3 and in cervical squamous cell carcinoma |
| Q33362569 | Interaction between polymorphisms of the human leukocyte antigen and HPV-16 variants on the risk of invasive cervical cancer |
| Q80421490 | Interferon-gamma (IFN-gamma): a possible prognostic marker for clearance of high-risk human papillomavirus (HPV) |
| Q81270434 | Inverse correlation of cellular immune responses specific to synthetic peptides from the E6 and E7 oncoproteins of HPV-16 with recurrence of cervical intraepithelial neoplasia in a cross-sectional study |
| Q34045548 | Low-dose adenovirus vaccine encoding chimeric hepatitis B virus surface antigen-human papillomavirus type 16 E7 proteins induces enhanced E7-specific antibody and cytotoxic T-cell responses |
| Q27002467 | Mechanisms of virus immune evasion lead to development from chronic inflammation to cancer formation associated with human papillomavirus infection |
| Q34089071 | Natural HPV immunity and vaccination strategies |
| Q33842444 | Nonspecific down-regulation of CD8+ T-cell responses in mice expressing human papillomavirus type 16 E7 oncoprotein from the keratin-14 promoter. |
| Q28389399 | Overcoming Barriers to Cervical Cancer Screening Among Asian American Women |
| Q92715593 | Papillomavirus Immune Evasion Strategies Target the Infected Cell and the Local Immune System |
| Q36677490 | Perceived stress is associated with impaired T-cell response to HPV16 in women with cervical dysplasia |
| Q34343006 | Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine |
| Q43412275 | Repetitive and consistent cervicovaginal exposure to certain viral pathogens appears to protect against their sexual acquisition in some women: potential mechanisms |
| Q38291781 | Sequence variation and physical state of human papillomavirus type 16 cervical cancer isolates from Australia and New Caledonia |
| Q36672543 | Single-dose, therapeutic vaccination of mice with vesicular stomatitis virus expressing human papillomavirus type 16 E7 protein |
| Q43656092 | Spontaneous regression of CIN and delayed-type hypersensitivity to HPV-16 oncoprotein E7. |
| Q36615047 | T-cell responses to human papillomavirus type 16 among women with different grades of cervical neoplasia. |
| Q84148682 | TNF-α and IL-10 promoter polymorphisms, HPV infection, and cervical cancer risk |
| Q40444191 | The Interaction Between Human Papillomaviruses and the Stromal Microenvironment |
| Q25257248 | The allelic distribution of -308 Tumor Necrosis Factor-alpha gene polymorphism in South African women with cervical cancer and control women |
| Q34956064 | The cell-mediated immune response to human papillomavirus-induced cervical cancer: implications for immunotherapy. |
| Q33848178 | The immunology of animal papillomaviruses |
| Q35006190 | The status of HPV16-specific T-cell reactivity in health and disease as a guide to HPV vaccine development |
| Q33944133 | Time course of humoral and cell-mediated immune responses to human papillomavirus type 16 in infected women |
Search more.